SCHEMBL6623939

SCHEMBL6623939

CCCc1ccc(S(=O)(=O)Nc2ccsc2CC(=O)N2CCOCC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.54
ALDH1A1 P00352 6/20 0.52
KMT2A Q03164 3/20 0.52
MAPK1 P28482 1/20 0.52
NPSR1 Q6W5P4 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.41
PABPC1 P11940 1/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6612972 0.90 HPGD (0.53) TSHRALDH1A1KMT2ALMNAGAA
SCHEMBL6624267 0.89 ALDH1A1 (0.43) TSHRALDH1A1KMT2AMAPK1LMNA
SCHEMBL6697059 0.87 ALDH1A1 (0.41) TSHRALDH1A1KMT2AMAPK1LMNA
SCHEMBL6697057 0.87 ALDH1A1 (0.41) TSHRALDH1A1KMT2AMAPK1LMNA
SCHEMBL6623416 0.84 MAPT (0.53) ALDH1A1KMT2AMAPK1L3MBTL1LMNA
SCHEMBL6695816 0.83 LMNA (0.45) ALDH1A1KMT2AMAPK1L3MBTL1LMNA
SCHEMBL6623951 0.83 THRB (0.44) TSHRALDH1A1KMT2AMAPK1LMNA
SCHEMBL6623605 0.83 ALDH1A1 (0.55) TSHRALDH1A1KMT2AMAPK1NPSR1
SCHEMBL6626083 0.82 ALDH1A1 (0.41) TSHRALDH1A1KMT2AMAPK1NPSR1
SCHEMBL6610854 0.82 TSHR (0.54) TSHRALDH1A1KMT2AMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 TSHR 4127/4885ALDH1A1 47/4885KMT2A 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.